Federal Register / Vol. 89, No. 206 / Thursday, October 24, 2024 / Notices 84899 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

NEPA EID Checklist ............................................................ 1,500 1 1,500 1 1,500 

Total .............................................................................. 1,500 ........................ 1,500 ........................ 1,500 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions; (2) the accuracy of the 

estimated burden; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–24732 Filed 10–23–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Evaluation and Testing 

Services for Vaccines and Other Biologics for 

Infectious Diseases (N01). 

Date: November 19–December 12, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G76, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Marci Scidmore, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G76, Rockville, MD 

20892, (240) 627–3255, marci.scidmore@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 21, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24744 Filed 10–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development. 

The meeting will be open to the 

public as indicated below. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), title 5 U.S.C., as amended for 

the review, discussion, and evaluation 

of personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development. 

Date: December 6, 2024. 

Open: 10:00 a.m. to 12:40 p.m. 

Agenda: Scientific Director’s Report on the 

status of the NICHD Division of Intramural 

Research and current organizational 

structure. 

Closed: 12:40 p.m. to 2:45 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Address: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

31 Center Drive, Room 2A03, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Chris J. McBain, Ph.D., 

Scientific Director, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 31 Center Drive, Room 2A03, 

Bethesda, MD 20892, (301) 594–5984, 

mcbainc@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: https://

www.nichd.nih.gov/about/advisory/bsc, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: October 21, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24743 Filed 10–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Muscular Dystrophy 

Coordinating Committee (MDCC). 

This will be a hybrid meeting held inperson and virtually and will be open to 

the public as indicated below. 


lotter on DSK11XQN23PROD with NOTICES1
84900 Federal Register / Vol. 89, No. 206 / Thursday, October 24, 2024 / Notices 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following link: https://

videocast.nih.gov/. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: November 22, 2024. 

Time: 9:00 a.m. to 4:00 p.m. ET. 

Agenda: The purpose of this meeting is to 

bring together committee members, 

representing government agencies, patient 

advocacy groups, other voluntary health 

organizations and people with lived 

experience to discuss topics of interest to the 

muscular dystrophy communities and 

renewal of the committee’s strategic plan, the 

Action Plan for the Muscular Dystrophies. 

The committee will discuss gaps and 

opportunities to better understand the 

muscular dystrophies, advance treatments 

and improve the lives of affected individuals. 

Registration: To register, please go to: 

https://web.cvent.com/event/ebf9b0d2-a61e400b-b8d9-5624d3d51f28/summary. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Room 1255/1265, Rockville, MD 

20852 (In-person and Virtual Meeting). 

Contact Person: Glen Nuckolls, Ph.D., 

National Institute of Neurological Disorders 

and Stroke (NINDS), NIH, 6001 Executive 

Blvd., Rockville, MD 20852, 301–496–5876, 

glen.nuckolls@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal facility 

will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Muscular Dystrophy Coordinating Committee 

website https://mdcc.nih.gov/, where an 

agenda and any addition information for the 

meeting will be posted when available. 

Dated: October 18, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24642 Filed 10–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Implementation Cooperative Agreement (U01 

Clinical Trial Required). 

Date: November 22, 2024. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G11, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Barry J. Margulies, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G11, Rockville, MD 

20892, (301) 761–7956, barry.margulies@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 21, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24745 Filed 10–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

HHS Approval of Entities That Certify 

Medical Review Officers 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: This notice publishes a list of 

the Department of Health and Human 

Services (HHS) approved Medical 

Review Officers certification entities. 

The most recent HHS Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs (Mandatory 

Guidelines), effective on October 10, 

2023 (Oral Fluid) and February 1, 2024 

(Urine), address the role and 

qualifications of Medical Review 

Officers (MROs) and HHS approval of 

entities that certify MROs. 

DATES: HHS approval is effective 

October 24, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Joshua Hunt, Pharm.D., MPH, LCDR, 

United States Public Health Service, 

Area/Regional Pharmacy Consultant, 

Substance Abuse and Mental Health 

Services Administration, 5600 Fishers 

Lane, Rockville, Maryland 20857; 

Telephone: (301) 642–9354; Email: 

Joshua.hunt@samhsa.hhs.gov. 

SUPPLEMENTARY INFORMATION: Subpart 

M—Medical Review Officer (MRO), 

Section 13.2 of the Mandatory 

Guidelines, ‘‘How are nationally 

recognized entities or subspecialty 

boards that certify MROs approved?’’ 

states as follows: ‘‘All nationally 

recognized entities or subspecialty 

boards which seek approval by the 

Secretary to certify physicians as MROs 

for Federal workplace drug testing 

programs must submit their 

qualifications, a sample examination, 

and other necessary supporting 

examination materials (e.g., answers, 

previous examination statistics or other 

background examination information, if 

requested). Approval will be based on 

an objective review of qualifications that 

include a copy of the MRO applicant 

application form, documentation that 

the continuing education courses are 

accredited by a professional 

organization, and the delivery method 

and content of the examination. Each 

approved MRO certification entity must 

resubmit their qualifications for 

approval every two years. The Secretary 

shall publish at least every two years a 

notice in the Federal Register listing 

those entities and subspecialty boards 

that have been approved.’’ 

HHS has completed its review of 

entities that certify MROs, in 

accordance with requests submitted by 

such entities to HHS. 

The HHS Secretary approves the 

following MRO certifying entities that 

offer MRO certification through 

examination: 

American Association of Medical 

Review Officers (AAMRO), 1506 E. 


lotter on DSK11XQN23PROD with NOTICES1